2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status
Bazhenova L, Hodgson J, Camidge D, Langer C, Huber R, Kim D, Reckamp K, Ahn M, Tan D, Patel J, Vincent S, Li C, Humphries M, Zhang P, Rivera V, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clinical Lung Cancer 2025 PMID: 40582920, DOI: 10.1016/j.cllc.2025.05.016.Peer-Reviewed Original ResearchObjective response rateProgression-free survivalMedian progression-free survivalALK-positive NSCLCCirculating tumor DNAALK mutationsALK fusionsMutation statusALK-positive non-small-cell lung cancerNon-small-cell lung cancerPlasma circulating tumor DNAActivity of brigatinibBaseline tumor samplesSecondary ALK mutationsMechanisms of resistanceALK alterationsALK amplificationALK inhibitorsPhase 1/2Preclinical activityTumor DNABrigatinibTumor samplesLung cancerTumor tissuesUse of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.
De Placido P, Hughes M, Weipert C, Sammons S, Morganti S, Parsons H, Abravanel D, Giordano A, Smith K, Patel A, Kirkner G, Stever C, Suggs G, Sendrick K, Snow C, Winer E, Tolaney S, Lin N, Jeselsohn R. Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance. Journal Of Clinical Oncology 2025, 43: 1075-1075. DOI: 10.1200/jco.2025.43.16_suppl.1075.Peer-Reviewed Original ResearchMetastatic breast cancerCirculating tumor DNACopy number lossHR+/HER2- metastatic breast cancerAcquired ResistanceEndocrine therapyLiver metastasesGenomic profilingCDKN2A copy number lossHormone receptor-positive/HER2-negativePlasma circulating tumor DNADuration of endocrine therapyPresence of liver metastasesIntrinsic resistanceCompare genomic profilesBaseline TFPlasma samplesAcquired endocrine resistanceMetastatic breast cancer diagnosisStandard-of-careCox regression modelsESR1 fusionsTumor sheddingSecond-lineMedian duration
2024
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. PMID: 40027305, PMCID: PMC11863946, DOI: 10.1016/j.jlb.2024.100168.Peer-Reviewed Original ResearchTriple negative breast cancerResidual cancer burdenCirculating tumor DNANegative breast cancerPathological responsePost-NACBreast cancerPlasma circulating tumor DNATriple negative breast cancer patientsResidual cancer burden scoreCirculating tumour DNA fractionPost-neoadjuvant chemotherapyPre-NAC samplesWeekly nab-paclitaxelTumor DNA methylation profilesTumor DNA fractionHot spot mutationsYouden's J statisticNab-paclitaxelPre-NACTumor variantsTumor DNATumor fractionClinical trialsDNA methylation profiles
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply